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Mutationsarising n viuvoinrecordergenesofhumanbloodcellsprovidebiomarkersformlecularepidemiologybyserv-
ingassurrogatesforcancer-causinggeneticchanges. Currentmarkersincludemutationsoftheglycophorin-A(GPA) or
hemoglobin(Hb)genes,nmasuredinredbloodcells, ormutationsofthehypoxanthine-guaninephosphoribosyltransferase
(hp,t)orEHLAgenes, measredinT4ymphocytes. Meanmutantfrequencies(variantfrequencies) fornormalyoungadults
areapproximately: Hb (4 x10`) < hprt(5 x 10') = GPA(10 x 10') <HLA(30 x 10 . Mutenposed individuals
showdecidedelevations. Molecularmutational spectraarealsobeingdefined. Forthehpit markersystem, about 15%
ofbackgroundmutatin aregrossr al alterations ofthehptgene (e.g.,ddetion);theremainderarepoint mutations
(e.g., basesubstitutions orframeshifts). Ionizingrdiationsresultindoserelated increasesintotalgenedeletions. Large
deletionsmayencompass severalmegabasesasshownbyco-deletionsoflinkedmarkers.Possiblehpitspectra fordefin-
ingradiationandchemicalexposuresarebeingsought. Inadditiontotheirresponsvenesstoenvironmental utagens/car-
cinogens, threeadditionalfmdingssuggestthatthein vivorecordermutationsarerelevantin vivosurrogatesforcancer
mutations. First, alargefractionofGPAandHLAmutationsshowexchangesduetohomologousrecombination, anim-
portantmutationaleventincancer. Second,hprtmutationsarisepreferentially individingT-cells, whichcanaccumulate
additionalmutationsinthesameclone,reminiscentofthemultiplehitsrequiredintheevolutionofmalignancy. Finally,
fetalhpit mutationsfrequentlyhavecharacteristicdeletionsofhpltexons2and3,whichappeartobemediatedbytheVDJ
recombinasethatrearrangestheT-cellreceptorgenesduringthymicontogeny. Illegitimateeventssuchasthesealsoap-
peartooccur inhuman leukemias.
Introduction
Molecularepidemiology is anattempttocombinethedisease
relevanceoftraditional epidemiologywiththe useofbiomarkers
to overcomelimitations instudying diseasesthat areinfrequent
orhavelongincubationperiods. Biomarkers measurethein vivo
effects ofdeleterious environmental agents and may even serve
as surrogates for disease. However, interpretation of human
studies is dependent on the biomarker employed. Does it sen-
sitively detect exposures? Is there any specificity? Does the
biomarkerdetectonly exposure ordoes itrevealin vivotoxicef-
fects that, while not disease effects, help to predict them?
Answers, ofcourse, require anunderstanding ofthebiology of
the biomarkers.
Some human cancers areundoubtedly caused, atleastinpart,
bygenotoxiccarcinogens. Human exposures totheseagents can
be monitored by biomarkers of chromosome or gene level
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damage, or through direct assessments of DNA damage,
chemicaladduction, orrepair. Thisreviewwillconsiderapar-
ticularsubsetofthese, i.e., geneleveldamage. Specifically, we
willfocusonthemeasurementandanalysisofsomaticcellgene
mutations arising in vivoinhumanbloodcells. Althoughall of
the assays for human monitoring will be considered, the em-
phasis will be on in vivo hypoxanthine-guanine phosphori-
bosyltransferase (hprt) mutations in T-lymphocytes.
Cells Used forStudies of Current
Biomarkers of in Vivo Somatic Cell
Mutations in Humans
Atpresent, mutationsarescoredasmutantcellsinperipheral
blood, i.e., redbloodcells (RBCs) orT-lymphocytes (T-cells)
(Table 1). However, the mutations giving rise to these mutants
ariseinprogenitorcells. FortheRBCassays, mutationsarisein
multipotent stem cells or in somewhat differentiated he-
matopoietic precursorcells inthebonemarrow. Continual pro-
liferationanddifferentiationofthesemutantprogenitorsproduce
theperipheral blood RBCs scored inthe assays. For the T-cell
assays, mutationsinadultsariseindifferentiated, matureT-cells
(1), probably in lymph nodes orotherbody tissues. Although
fully differentiated, these cells retain the capacity for limitedALBERTINIETAL.
Table 1. Characteristics ofcells used inassays forhuman in ivo
somatic mutations.
Mutant Target cells for Body compartment Metabolic competence
cells mutation for mutation oftarget cell
RBC Multipotent stem Bone marrow Probable, also, stem
cell, differenti- cell surroundedby
ated precursor competent
cell macrophages
T-cell Post-thymic Blood Competent (partial?)
(adults) Mosttissues Proximity to other
Prethymic (fetus) Bone marrow tissues
Thymus (?)
but repetitivecell division after stimulation in vivo (usually by
antigen), providing expanded clonesderivedfromoriginalpro-
genitors. MutantT-cellsderiving frommutations inexpanding
clones make up a greater or lesser fraction of these clones,
depending on when theyoccurduringclonalexpansion. Inthe
fetus, however, and presumably in children and adolescents,
mutations may arise in pre- or intrathymic pre-T-cells. The
prethymic progenitors ofT-cells may evenbebonemarrowstem
cells, in which case the kinetics ofappearance andpersistence
ofT-cell mutants in peripheral blood will be similar to what is
seen for RBC mutants.
Thedifferentiation stageofmutational targetcells relativeto
the mutants scored inanassay determines somecharacteristics
ofthat assay's results [reviewed inAlbertini etal. (2)]. For ex-
ample, mutations arisingin stemcellscontinuouslyproducemu-
tantprogeny. Therefore, acharacteristic ofstem cell mutations
forhumanmonitoring ismemory, i.e., mutationsarising inthe
distantpastcanbedetected. Costsofmemory, however, include
variability, determined inpartbythenumberofstemcells pro-
ducingthepopulationofmaturecellssampledatanygiventime,
andlossoftemporal relationships between induced mutational
eventsandthedetectionofmutantsinperipheralblood. Incon-
trast, mutationsarisingindifferentiatedT-cellsaremoreclosely
relatedintimeto thepresenceofmutantcells in theperipheral
blood, especially ifthereisafinitelifespanofmutants. Thecost,
ofcourse, is memory.
MatureRBCshavelosttheirnucleus. There is, therefore, no
possibility formolecularstudiestodefinemolecular spectraof
mutations. Theterm "variants" acknowledges this. T-cells, how-
ever, can be propagated in vitro and studied at the molecular
level. Also, the T-cell receptor (TcR) genes, which rearrange
during thymic differentiation of individual T-cells, may be
analyzedinthesecellsrelativetomutations(1). Thisallowsdeci-
sionstobemaderegardingtheinvivoindependenceofdifferent
mutant isolates and the differentiation stage in vivo when the
mutation occurred.
Thereisprobablymetaboliccompetency forthetargetcellsfor
both the hematopoietic and T-cell mutations. Hematopoietic
precursor cells are surroundedby metabolically active macro-
phages in the bone marrow. Mature T-cells are partially
metabolically competentandcirculatethroughallofthetissues,
where they areprobably exposed to mutagenic metabolites.
Table2. Human in Wvo somatic mutation assays.
Target gene
B chain of
hemoglobin
(Hb beta)
Glycophorin A
(MN blood
group antigen)
Target
size
2 kb,
3 exons
(50)
44 kb,
7 exons
(53)
Hypoxanthine- 44 kb,
guanine 9 exons
phosphoribosyl (55)
transferase (hprt)
HLA-A (major 5 kb,
histocompatibili- 7 exons
ty genes) (59)
Chromosome
location
llpl5.5,
autosome
(51)
4q28-31,
autosome
(51)
Xq26,
X-chromosome
(51)
6p2l.3,
autosome
(51)
Assay method
HbA (normal) - HbS (sickle cell Hb) mutations are
detected by fluorescent anti-HbS antibody treatment
offixed RBCs on slides. The rare fluorescentcells in
a HbA/HbA homozygous individual are scoredby an
image analyzer (52).
Anti-M and anti-Nantibodies, labeled with greenand
red fluorophors, respectively, are used todouble label
wild-type (nonmutant) RBCs from M/Nheterozygous
individuals. Asingleordualbeamcell sorterdetectsthe
lossofeitherantigen(MOorNO)(hemizygous)ordouble
expressionoftheother(MMorNN)(homozygous). The
first is due to simple allele loss; the second is due to
somatic recombination or gene conversion (54).
The short-term assay measures first-round DNA syn-
thesisofstimulatedT-cellsinvtroin6-thioguanine(TG)
by either autoradiography or BrdU incorporation.
Labeledcellspresumably haveundergone in vwvohprt
mutation (19).
Forthe cloning assay, direct cloningofT-cells is per-
formedwith orwithout6-TG inthepresence ofT-cell
growth factorand feedercells (56-58).
HLAmutants aredetectedby directcloningofT- cells
after their treatment with anti-HLA monoclonal an-
tibodies toeliminatewild-typecells (60).
End Range of
point mean values
Vf 4 X o-a
(17)
Vf 10 x 10-6
(hemizygous)b
10-20 x 10
(homozygous)C
(3)
Vfd 2-9 x 10 6
(2)
Mf 3-10 xlO-6
(2)
Mf 30 x 10-6
(6)
Abbreviations: Vf, variant frequency; Mf, mutant frequency.
aSingle study.
bHemizygous mutant = single loss (see text).
CHomozygous mutant = loss with gain ofhomologous allele (see text).
dShort-term autoradiographic assay (see text).
Genetic
assay
HbS
(RBC)
GPA
(RBC)
hprt
(T-cells)
HLA
(T-cells)
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Assays Used for Studies of Current
Biomarkers of in Vivo Somatic Cell
Mutations in Humans
Four assays are currently available for measuring in vivo
somatic cell gene mutations inhumans(Table2). Anunderstan-
ding ofthe biology ofeach assay is important for its interpreta-
tion, especially for comparing results across assays. The muta-
tional targetsizes ofthe four genes studied inthese assaysdiffer.
The Hb gene is 2 kb in length; however, the functional target
sizeforthemutation currently scoredisa singlebasechange. The
glycophorin A(GPA) andhprt genes are approximately equal in
size; however, forGPA, the immunological methods used inthe
assay define target size by theantibody usedandtheprotein struc-
tures required for recognition, whereas forhprt, chemical selec-
tion for mutants requires lossofcatalytic activity oftheHPRI en-
zyme, which may not occur following all possible mutations of
the gene. For HLA, although this is, in principle, another large
target gene, the immunological methods used for mutantdetec-
tion make it difficult to define target size.
Autosomal genes (hemoglobin[Hb], GPA, HLA) allow forthe
detection ofinterhomologous chromosome mutational events,
such as somatic recombination and gene conversion, in addition
to the more commonly considered mutational events, thus pro-
viding surrogates for events that may be important in the genesis
of cancer. In contrast, the hprt gene is on the X-chromosome,
which is either actually or functionally hemizygous in all mam-
malian cells; therefore, interhomologous chromosome muta-
tional events cannot occur at hprt. Results, to be considered
below, should be interpreted in light of these biological char-
acteristics.
Quantitative Aspects
Studies from several laboratories have reported background
mutant or variant frequency values (Mf; Vf) for normal adults
(Table 2). Background mutations are not synonymous with spon-
taneous mutations because the causes are not known. However,
the terms are often used interchangeably. In summary, the
relative orderofbackground Mf(Vf) values from normal adults
forthe several markers is: Hb > hprt = GPA > HLA. Age-
related increases in these values have been reported for GPA,
hprt, and HLA (3-7).
Qualitative (Molecular) Aspects
T-cells canbe recovered from cloning assays and propagated
in vitro into populations ofsufficient size formolecular analyses.
Although this has been accomplished for both hprt and HLA
mutations, the largest database at present is for hprt.
hprt. There has been quite good aggreement among labora-
toriesthatapproximately 15% ofhprtmutations in normal adults
result from gross structural alterations (2,8-11). These include
deletions, insertions, and rearrangements visible on Southern
blots. The breakpoints ofthe alterations aredistributed randomly
within the gene, with no "hot spot" thus faridentified (2). Total
deletions of hprt may show co-deletion of linked anonymous
markers, which map several centiMorgans distant inboth 5' and
3' directions, indicating that deletions can be quite large (12).
Theremaining 85% ofthebackgroundinvivohprtmutations
inadultsconsistofpointmutations. Becauseoftheimportance
ofhprtas agenetic target, a repository has been established to
collate information on in vivo and in vitro mutations in human
cells developed in all laboratories engaged in such studies
worldwide (13). More than 700 such mutants have been seq-
uencedtodate. Themutationscharacterized includemorethan
200 somatic mutations derived from normals, smokers,
chemotherapy patients, and patients with the DNA repair
disorders xeroderma pigmentosum and ataxia telangiectasia.
Fifty-sevengerminal hprtmutations (Lesch-Nyhan syndrome)
alsohavebeencharacterized. In addition, severalhundredhprt
mutationsgeneratedin vitroby agentsincludingethylnitrosourea
methyl-N-nitroguanidine, formaldehyde, ICR-191, cyanoethylene
oxide, cisplatin, benzo[alpyrene diol epoxide, and UV lighthave
been sequenced. The datacollected todate suggestthathprtis
sensitive to all mutation types, including basepairsubstitutions,
frameshifts, and deletions ofvarious sizes. A total of227 dif-
ferent base substitutions have been observed at 172 ofthe 657
bases ofthe coding region. Ofthese, approximately 85% were
missense mutations, 13% nonsense mutations, and 2% did not
leadtoany aminoacidchange. (The latter class ofmutations may
express phenotypically due to codon usage problems or due to
decreased stability oftheresulting hprtmRNA.) Every class of
base substitution has been observed at similar frequencies and
wasdistributed throughoutthe coding region inallnineexons of
hprt. Thirty-eight frameshifts (25 -1, 13 +1) involving both GC
and AT base pairs have been observed. In general, frameshift
mutations occurred at oradjacent to sequences containing two
or more consecutive identical bases. Thirty-one examples of
small deletions (2-49 bases) wererecorded. Mostofthesedele-
tions were flanked by 2-5 base direct repeat sequences. More
than 150mutants displaying splicing aberrations havebeen iden-
tified. Theseincludeexamples ofsingle, multiple, andpartial ex-
on loss and involve all exons except exon 1. (Exon 4 [28%] and
8[30%] aremostfrequent.) Tenoffourteen sequenced exon loss
mutants displayed base substitutions at the splice acceptor or
donor regionofthemissing exon. The remaining mutations most
likely containpointmutations or smalldeletions within other in-
tron sequences involved in splicing.
Consideringonly theinvivomutations (46 Lesch-Nyhan ger-
minal, 51 normal adult somatic, 86 exposed adult somatic),
several hotspots ofmutation were observed. In particular, four
basespair sites have been observed tobe mutated in all groups.
However, anadditional 132 sites havebeen recorded with only
a single observation per site. This suggests that there are many
more sites inhprt thatroutinely mutateinviw (perhaps 100-200
additional sites), although the total number ofin vivo mutations
analyzed to date is not large enough to have observed them all.
HLA. Approximately 30% ofthe background mutations in
adults result from total deletions of the gene as detected on
Southern blots (14). At HLA also, some deletions appear to be
quitelarge, asdemonstrated by theassociated phenotypic loss of
the HLA-B antigen codedby theallele in "cis" withthe deleted
HLA-Aallele. Thus, deletions of> 1000kb are seen. More im-
portantly, recentmolecularanalysesofin vivo-derived HLAloss
mutants show that approximately 30% also arise from mitotic
recombination (15). Therefore, this importantclassofmutations
canberecognizedatthemolecularlevel. Atpresent, there are no
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published sequencedataonin vivoHLAmutationsdefiningthe
nature ofpoint mutations at this locus.
SomaticCell Gene MutationsInduced
in Vivo by Environmental Mutagens
The utility ofthe assays ofin vivo somatic mutation for en-
vironmental monitoring isbeingassessedbydefinirgtheirability
to detect human exposures to model mutagens, e.g., smoking,
cytotoxicchemotherapy andionizingradiations, ortogenotox-
ic agents in well-defined accidents. Most investigations have
shownclearincreasesinVforMfvalues inexposedindividuals.
Effects ofSmoking
Definite increases in in vivo hprt Mfvalues due to smoking
havebeenreportedby severallaboratories(5,16-18). Infact, this
increase was greater than 50% in smokers compared to non-
smokers inonestudy (16). Otherstudies, however, havereported
weakerornoeffects (19,20). Smokingalsoresultsinsomewhat
higherGPAVfvaluesthanfornonsmokers, but, inmoststudies,
this increasedoes not achieve statistical significance (3). Pre-
liminary results inethyleneoxideworkers andataxiatelangiec-
tasiaandxerodermapigmentosumheterozygotes suggestthatin
smokers thefrequency ofHbS variantcells is doubled as com-
pared to nonsmokers (21).
ExposuretoCytotoxic Chemotherapeutic Agents
Moststudiesofcancerpatientsundergoingchemotherapyhave
shownclearincreasesinhprtT-cellMfvalues(22-24). Asimilar
increasehasbeen seenforGPA mutations (25). However, are-
centstudy of31 breast cancerpatientsreceiving eitherchemo-
therapy, radiotherapy, orbothreportednosignificantincreasein
hprt Mfattributable tochemotherapy (26). Thesignificant in-
creases seenintreatedpatientscouldbeaccountedforsolelyby
radiotherapy. Two of the agents received by these patients,
cyclophosphamide and adriamycin have been implicated as
mutagens inother studies ofin vivo somatic mutation (25,27).
We have recently completed a similar study ofwomen with
breastcancerreceivingpotentiallymutagenictherapies, andwe
obtainedquitedifferentresults(20,28). Allpatientsinourstudy
had surgerywithcurativeintent; subsequenttherapy wasinthe
adjuvantmode. Group 1 patientshadnotherapybeyondsurgery,
orhadhormonaltherapy, group2patientshadlocalradiotherapy
with or without hormonal therapy, and group 3 patients had
chemotherapy with orwithoutradiotherapy and/orhormones.
Thefirstbloodsamplewasobtainedaftersurgerybutbeforethe
onsetofadjuvanttherapy; subsequentsamples wereobtainedat
6-month intervals. Womenpresentingwith noncancerousbreast
masses served as controls.
Incontrasttothestudynotedabove,therewasasignificantin-
creaseinmeanMfat6monthsinwomenreceivingchemothera-
py (18.2 ± 1.7 x 10-6)comparedtoprechemotherapy (11.1 ± 1.4
x 10-6). Amoremodestincreaseinmeanpost-treatmentMfwas
seenafterlocalradiotherapy, butneitherthis, northeslight in-
crease in the group patients, reached statistical significance.
Following chemotherapy, hprt Mf values returned toward
baseline, butremained somewhat elevated.
Comparisonofthetwohprtstudiesofbreastcancerpatients
revealsfactorsthatmaybeofimportanceininterpreting in vivo
mutagenicity studies. In the study showing no significant
chemotherapyeffects, thetimeofassayrelativetochemotherapy
was variable. Timing is probably extremely important for op-
timallydetectinghprtmutantT-cellsinperipheralblood. Sam-
plinglongafteranexposuremaywellunderestimatehprtmuta-
tioninduction. Also, someofthisdifferencewasduetothekind
ofchemotherapy received, with fluorouracil and methotrexate
producing littlemutagenicity. Inaddition, individual factors may
alsobeofimportance, suchasserumfolatelevelsinthedeficien-
cy range, which wereparticularly common in thewomen who
hadthemostmarkedMfelevatiqnsafterchemotherapy. Atpre-
sent, therearenopublishedreportsofmolecularanalysesofhprt
mutations following a specific cancer chemotherapy or other
formofin vio chemical mutagenesis. However, several studies
areinprogress (seeaboveforsummaryofcurrentsequence in-
formation). Theexpectationisthatdifferentchemicalmutagens
willbeshowntoinducedifferentmolecularspectraofmutations,
thereby producing signatures forspecific recognition.
Exposures to IoniingRadiation
hprt. Mfshavebeenstudied inseveral groupsofhumansex-
posed to ionizing radiation (24,27,29-32). Induced mean fre-
quenciesinexposedindividualshavevariedfromalowof7.5 x
io-9 to a high of5.5 x 10-6/cGy. This range ofalmost three
ordersofmagnitude illustrates, intheextreme, theimportance
oftiming in measuring in vivo-induced hprt mutations in pe-
ripheralbloodT-cells. Therateofinductiondetermined inser-
vivors of the atomic bomb explosion is 7.5 x 10-' and was
determinedalmost45yearsafterthemutantswereinduced(32).
Eliminating thisstudyrevealstherangeofhprtmutantinduction
by ionizing radiation to be approximately 1-5 x 10-6/cGy for
high-dose, low linearenergy transferirradiations.
TheGPAassay was alsoused in studies ofatomic bomb sur-
vivors45yearsaftertheevent(33,34). Thesestudiesrevealedan
increment ofapproximately 0.4 x 10-6 induced GPA mutant
RBCs/cGy, even at this late date, with a good deal ofinterin-
dividualvariability. SuchresultsinRBCsareinaccordwithstem
cell mutations, discussedabove.
In an effort to better define the in vivo mutagenic effects of
ionizing radiation, our laboratory has determinedhprt Mfs in
cancerpatients exposedto an internal y-emitting radionuclide
(131') (radioimmunotherapy [RT)producingtotalbodyirradia-
tioninanexponentially decayingdose(35,36). Wedetermined
Mfvalues in 13 patientsbeforeand 36patients aftertreatment.
Thepost-treatmentgroupincluded 11 samplesobtained2months
afterafirsttreatmentof62-104cGy, 18samples2monthsafter
the last ofa series ofmultiple treatments (cumulative total of
128-669cGy), and7 samplesobtained 10-48 months afterthe
lastofmultiple treatments (cumulative total of 128-324 cGy).
Basedoneitherthedoseofthefirstsingletreatmentorthe last
of the multiple treatments, a dose-response relationship of
0.9-1.1 x 10-6 mutants/cCy was seen. Based on the total
cumulativeexposure, thisinductionfeilto0.2-0.3 x 10' inthe
2-month samples, and to 0.09 x 10-6 in the 10-48-month
samples. (This dose response compares with a value of0.2 x
10-6mutants/cGy inT-cellsacutely irradiated in vitro.) These
time-dependent declines in the in viw Mf point again to the
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Table3. Gross structural alteration in in viwv hprtmutations.
Change on Southern blot
Total Partial Single New fragment No % Gross
Subject deletion deletion breakpoint only change Total alteration
Normals 9 (22%) 20 (49%) 9 (22%) 3 (7%) 246a 287b 14.2
pre-RIT 3 (15%) 10(50%) 6 (30%) 1 (5%) 98 118 16.9
post-RIT 37 (41%) 27 (30%) 22 (24%) 4(4%) 145 235 38.3
RIT, radioimmunotherapy.
aIndependent mutations without visible alteration onSouthern blot.
bTotal independent mutations studied forthegroup.
importance of sampling time in human in vivo mutagenicity
studies. Nonetheless, in vivo exposures towhole-body ionizing
radiation clearly result indose-dependent increases inhprtMf.
Ionizing radiation is known to inducegross structural altera-
tions in hprt and other recorder genes in cultured human and
othermammaliancells. Bradley etal. (8)foundanincreasedfre-
quency ofmutants with gross structual alterations on Southern
blots inpatients who hadreceived radionuclides fordiagnostic
purposes (33%) as compared to patients before receiving ra-
dionuclides (13%). Inatomicbombsurvivors, thefrequenciesof
mutationsshowinggrossstructuralalterationsathprtwereessen-
tially the sameinindividualsexposedtoradiation fromthebomb
compared to nonexposed controls (9); however, as noted, the
study was conducted almost45 yearsafter the exposure.
Ourlaboratory recentlycompleted ananalysisof241 indepen-
dentin vivohprtmutational events, isolatedfrom 19RITpatients
(35,36). The hprt molecular lesions in these mutations were
compared withthehprtmolecularlesionsin 118invivomutations
from 4 cancer patients before their therapy and in 287 back-
groundin vivomutationsinnormalyoungmales (Table3). The
mutations from post-RIT patients showed clearly greater fre-
quencies ofgross structural alterationsthanthosefrompre-RIT
or normal individuals. The latter two frequencies are quite
similar, suggestingthatcancerpersedoesnotproducethis sort
ofdamage athprt.
This difference in the kinds of in vivo hprt mutations after
ionizing radiation, compared to in vivo mutations before ex-
posure or in normals, extends to the sizes ofthe molecular le-
sions. Post-RIT patients have muchhigherfrequencies oftotal
gene deletions. Therefore, not only is the frequency ofin vivo
mutations withgross structural alterations increasedafterioniz-
ingradiationexposures, thepercentageoflesionswithlargedele-
tions is increased. In individuals from whom 10 or more in-
dependentinvivohprtmutationscouldbeanalyzed, thecorrela-
tion between fraction ofmutations withgross structural altera-
tions and cumulative radiation dose was 0.79 (r = 0.82, r2 =
0.67 forthelinearregression). Therefore, inourstudies, 67% of
thevariability in fractionofin vivomutations withgross struc-
tual alterations could be explained by ionizing radiation
exposure.
Takenintoto, thedataforinvivohprtT-cellmutationsindicate
thationizingradiationproducesdeletionsandthatdeletions, par-
ticularly largedeletions, characterizethein vivomutational spec-
trum forthis sortofhumanmutagen exposure. There may also
be a characteristic point mutational spectrum for in vivo hprt
mutations resulting fromionizing radiation exposure. Sequence
studies are inprogress.
Occupational orResidentialMutagenExposures
Thereareseveralpublishedreportsofhumanmonitoring, us-
ingthehprtcloningassay, forin vivoeffects ofoccupational or
residential chemical or radiation mutagen exposures
(18,19,37-41). Forionizingradiation,mutationinductionappears
tobemoreefficientforlow-doseirradiations, beingintherange
of 10- inducedmutants/cGy in somestudiesalso(39-41). Oc-
cupationalexposurestochemicalmutagens(e.g., chemotherapy
nurses) resultedinelevationsinMf(18,37), butnotwhenspecial
precautions weretaken (19).
Arecent, well-controlledstudyoftheassociationbetweenhprt
MfinperipheralbloodT-cellsandhouseholdradonconcentra-
tions deserves special mention (38). A significant association
was found between the log Mf and radon concentration. The
doubling dose for Mf, estimated from two separate meas-
urementsofhouseholdradonconcentrations, was330Bq/m3 and
210Bq/m3, respectively. Theauthorscautionthatthesedatamust
be regarded as preliminary and that further, more extensive
studies shouldbedone. Molecular studiesofthesein vivohprt
mutations areclearly indicated.
Relevance of Mutation in Somatic
RecorderGenesto Cancer
Several featuresofsomaticcellgenemutationdiscoveredthus
far suggest that the recorder genes being studied serve as sur-
rogatesforcancer-causingmutations. First, consideredindetail,
is thefinding thatexposures to genotoxic carcinogens result in
elevations in Mf (Vf) and, for ionizing radiation, result in a
characteristic mutational spectrum. Also, two ofthe recorder
genes being studied, GPA and HLA, permit recognition of
somaticcellrecombinationand/orgeneconversion. Thesemuta-
tionaleventsareknowntobeimportantinthegenesisofcancer.
Two additional features indicating relevance to cancer are
demonstrated by studies ofhprt.
Analysisofbackgroundhprtmutationsinnormalindividuals
indicatesthatcelldivisioninvivoisanimportantmutagenicin-
fluence. Severalindividualswithinvivoclonalamplificationsof
T-cells, detected by concomitant studies of TcR genes, have
shownthatthehprtmutationsareoccurringwithintheexpanding
clone(1,2). Oneindividualwithamassiveclonalexpansionhas
shownfourdifferentmutational eventsinthissingleclone. This
suggests thatunremitting cell division can create space for se-
quentialgenemutationstoaccumulateindescendantsofthesame
cell. Perhapsthespontaneousmutationsresultingfromcopyer-
ror in cells stimulated to continual division have an important
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role inthegenesisofspontaneous humancancers, withtherole
ofenvironmental agents being to induce such cell division.
A more recentobservation comes from studiesoffetalin vivo
hprt mutations, as reflected by studies ofplacental cord blood.
Background Mfvalues fornewborns, determined inthis way, are
approximately 10-fold lower than for adults, i.e., 5 x 10-7
(16,42,43). Molecular analysesofthesefetal mutations showthat
they frequently arise inprethymiccellsandthattheirmutational
spectrum is characterized by specific deletions ofhprtexons 2
and 3, with deletion breakpoints giving rise to these deletions
ocurring at asingle site inintron 1 andat several sites in intron
3 (45). Thesiteshaveincommonall oranimportantportionof
the consensus heptamer [CAC(T/A)GTG] for the VDJ recom-
binasethatmediatescleavageoftheTcRgenesduringthymicon-
togeny (46). Other hallmarks ofaVDJ recombinase-mediated
cleavage event characterize thejunctional regions of the hprt
deletions. Therefore, anillegitimaterecombinase-mediated event
canoccurinthehprtgenewhich, whenoperative, accounts for
30% ormoreofthebackgroundmutations. Asimilareventhas
been shown tooccur inagrowth factorgene in25% ofacuteT-
cell leukemias (47,48), whereitmaybepathogenic, andasanin-
termediate toseveral ofthechromosomal translocations seen in
B-cell lymphomas (49). Thus, a mutagenic eventthat may be
termed developmental mutagenesis has been uncovered by
studies of in vivo hprt mutations in humans. Further studies
should reveal its relevance to human cancer.
Conclusions
The statusofin vivosomatic cell mutations asbiomarkers for
humanstudieshaschangedagooddeal in recentyears. Several
markers ofmutation are nowavailable, and more arecertain to
come. Also, insights havebeen obtained that give a somewhat
differentpicturethanthatderivedfromstudiesofin vitromuta-
tions. These insights have provided an understanding of the
biologyofthedifferentinvwvomutagenicity assaysinuse. Results
ofhuman monitoring studies can nowbe interpreted in lightof
thisbiologicalunderstanding. Theuseoftheseassaysinbasicin-
vestigations of somatic cell mutation, and its role in human
disease, is great.
The role of human in vivo somatic cell mutations as bio-
markers for genotoxic carcinogen exposures is also being
developed. Studies reviewedhereindicatethatmutationsarein-
ducedbyexposures totheseagentsandmaybequitesensitive in-
dicators ofsuchexposures. Themarkerscertainly areuseful as
population indicators of genotoxicity. Also, the ongoing
molecular studies ofin vivo-induced mutants may reveal char-
acteristic mutational spectra that will allow "diagnosis" of
specificdeleterious agents. Itmay evenbepossibleeventually to
makeindividual healthriskassessments followinggenotoxic ex-
posures, although thepotential forthis iscurrentlyunexplored.
Amajorgoal incontinuing studiesofin vivosomaticcell muta-
tion in humans remains the development of methods for
mutagenicity monitoringthatwill resultinhealthbenefits tothe
individuals studied.
This manuscript was presented at the Conference on Biomonitoring and
Susceptibility Markers inHumanCancer: Applications inMolecularEpidem-
iology and Risk AssessmentthatwasheldinKailua-Kona, Hawaii, 26October-i
November 1991.
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